Tag: CPAP Alternative
Rotech excited about CPAP alternative
December 20, 2024HME News Staff
ORLANDO, Fla. – Rotech Healthcare recently partnered with Signifier Medical Technologies to offer the eXciteOSA device as an alternative option for OSA, part of the provider’s commitment to serving all patients, says CEO Robin Menchen.
The eXciteOSA device allows daytime treatment for approximately 20 minutes twice a day for the initial treatment period, which is ideal for those patients who cannot tolerate CPAP treatment when trying to sleep, she said.
“Our...
Rotech to supply CPAP alternative
November 26, 2024HME News Staff
ORLANDO, Fla. – Rotech Healthcare has announced a supplier agreement with Signifier Medical Technologies to introduce the eXciteOSA device to payers, health care providers and patients to treat mild to moderate obstructive sleep apnea.
The eXciteOSA device, approved by the U.S. Food and Drug Administration, uses neuromuscular electrical stimulation to tone tongue muscles to maintain an open airway during sleep, improving sleep quality and overall health.
“Partnering...
Inspire Medical Systems gets green light for V
August 5, 2024HME News Staff
MINNEAPOLIS – Inspire Medical Systems has announced approval from the U.S. Food and Drug Administration for the Inspire V therapy system, which includes a next generation neurostimulator for the treatment of obstructive sleep apnea. The system also includes the associated Bluetooth patient remote and physician programmer. “We are thrilled to announce the FDA approval of our next generation Inspire neurostimulation system,” said Tim Herbert, chairman and CEO of Inspire Medical Systems....
Signifier’s CPAP alternative greenlighted by SC Medicaid
April 8, 2024HME News Staff
BOSTON – Signifier Medical Technologies has announced that its eXciteOSA therapy for sleep-disordered breathing is now covered by South Carolina’s Health Connections Medicaid program. This coverage opens new doors for patients 18 and older who have previously had limited access to advanced treatments for obstructive sleep apnea. "We are thrilled that eXciteOSA is now covered by Medicaid in South Carolina," states Akhil Tripathi, director and co-founder of Signifier. "This...
ProSomnus raises $10M
September 25, 2023HME News Staff
PLEASANTON, Calif. – ProSomnus, which makes a CPAP alternative for the treatment of obstructive sleep apnea, has completed a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital. The company will use the new capital to optimize its core business operations and support its strategic growth initiatives as it strives to achieve cash flow breakeven. “The completion of this financing fortifies our balance sheet as we continue...
Alternative OSA therapies? Providers are skeptical
April 7, 2023Theresa Flaherty, Managing Editor
YARMOUTH, Maine – Although alternative therapies to treat sleep apnea like nasal sprays, chest implants and dental appliances continue to flood the market, CPAP remains the gold standard, say HME providers.
In January, for example, Vivos Therapeutics received clearance from the U.S. Food and Drug Administration for its proprietary daytime-nighttime (DNA) appliance to treat OSA; in March, Inspire Medical, the maker of an FDA-approved neurostimulation device, received FDA approval to...
Inspire Medical sees significant growth in Q4
January 10, 2023HME News Staff
MINNEAPOLIS – Inspire Medical, the maker of an FDA-approved neurostimulation device to treat obstructive sleep apnea, expects revenue of $137.5 million to $137.9 million for the fourth quarter of 2022, about a 76% increase year over year. It expects revenue for the full year to be $407.5 million to $407.9 million, about a 75% increase compared to 2021. “We are very pleased with our strong preliminary revenue performance in the fourth quarter primarily driven by higher utilization at existing...
Vivos receives clearance for appliance to treat OSA
January 9, 2023HME News Staff
LITTLETON, Colo. - Vivos Therapeutics, a medtech company focused on developing innovative treatments for patients suffering from obstructive sleep apnea, has received clearance from the U.S. Food and Drug Administration for its proprietary daytime-nighttime (DNA) appliance. With FDA clearance, the DNA appliance offers a new treatment regimen that opens the airway by expanding the palate and training the tongue to rest in the proper position, converting patients to nasal as opposed to oral breathing. ...
Apnimed secures additional financing
January 3, 2023HME News Staff
CAMBRIDGE, Mass. – Apnimed has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million. The company will use proceeds to fund the planned Phase 3 trials for its lead candidate, AD 109 (aroxybutynin + atomoxetine), which has the potential to be the first oral treatment for obstructive sleep apnea. “This substantial additional investment is a significant vote of confidence by our investors,” said Larry Miller, M.D.,...
Oventus targets growth in North America with new hire
September 13, 2021HME News Staff
BRISBANE, Australia – Oventus Medical has appointed Michael Sisk as vice president of finance in the U.S. to support the increasing needs of the company’s North American operations. He brings more than 25 years of experience in finance and accounting, ranging from smaller banks to $8 billion publicly traded financial institutions. “Mike has built a strong track record of financial management with publicly traded organizations over many years,” said Dr. Chris Hart, founder...